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suggest that the FDA alone con-
trols access to experimental drugs, 
but major barriers to access lie 
beyond the agency’s jurisdiction. 
Manufacturers, for instance, wor-
ry about liability, and physicians 
may not seek such drugs for fear 
of the FDA paperwork. In addi-
tion, Medicare, Medicaid, and pri-
vate insurers generally will not 
pay for experimental drugs.
Pharmaceutical-industry repre-
sentatives also express other res-
ervations. “One of the biggest 
limitations is manufacturing ca-
pacity,” says Scott Lassman of 
the Pharmaceutical Research and 
Manufacturers of America. “Es-
pecially in very early phases, the 
company may still be working out 
how to manufacture the product.” 
Although the bill proposes al-
lowing companies to charge for 
tier 1 drugs, says Lassman, they 
certainly couldn’t charge full price. 
More important, “the whole pur-
pose of large clinical trials is to 
fully evaluate benefits and risks,” 
argues Frank Rockhold, an exec-
utive at GlaxoSmithKline, “and 
short-changing that is not in pa-
tients’ best interests.”
Nonetheless, the recent actions 
have apparently stimulated efforts 
to broaden access to experimen-
tal drugs within the current sys-
tem, especially in light of in-
creased demand from patients. 
“We’ve seen a significant increase 
in the treatment INDs that are 
requested,” says Scott Gottlieb, 
the FDA’s deputy commissioner 
for medical and scientific affairs. 
“The agency has generally been 
aggressive in granting those,” 
usually acting within 24 to 48 
hours on physicians’ IND requests 
and encouraging companies to 
establish broader treatment IND 
programs if there is considerable 
demand for a drug. According to 
Gottlieb, the agency is working to 
clarify the process of requesting 
access to experimental drugs, in 
part by providing standardized 
application forms and an inter-
face on the FDA’s Web site.
This spring, the National Co-
alition for Cancer Survivorship 
and the American Society for 
Clinical Oncology petitioned the 
FDA to issue guidance to the phar-
maceutical industry on standards 
for expanded-access programs; 
they suggested criteria for decid-
ing when such programs are ap-
propriate, ways to ensure equi-
tability, and approaches to data 
collection and informed consent. 
Gottlieb says that the FDA has 
created a task force to respond to 
the petition and is clarifying its 
rules regarding what companies 
may charge. The FDA is permitted 
to approve compassionate use only 
for diseases in which evidence 
suggests that a given medication 
may have efficacy. However, the 
agency hopes to persuade com-
panies to sponsor “simple, large, 
nonrandomized, open-access tri-
als” for certain drugs that are in 
phase 3 trials, or possibly late in 
phase 2 trials, to make them avail-
able to more patients while pro-
viding additional data. “We think 
that you can have an approval pro-
cess that is rigorous . . . even 
though you have parallel mecha-
nisms to allow broader access to 
a drug that has shown activity 
and promise,” Gottlieb says.
An interview with Mr. William Schultz, a 
partner at the law firm Zuckerman Spaeder 
and a former deputy commissioner for policy 
at the FDA, can be heard at www.nejm.org.
Dr. Okie is a contributing editor of the 
Journal.
Society for Clinical Trials Board of Direc-
tors. The Society for Clinical Trials opposes 
US legislation to permit marketing of un-
proven medical therapies for seriously ill pa-
tients. Clin Trials 2006;3:154-7.
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Related article, page 447 
The control and virtual elimi-nation of measles in the Unit-
ed States is a public health success 
that has provided a model for 
immunization programs in other 
parts of the developed world. Be-
fore measles vaccination was in-
troduced in the United States in 
the mid-1960s, more than half a 
million cases of measles were re-
ported each year. Once a vaccine 
was developed, public health of-
ficials set out to use it to control 
the disease, envisioning eventual 
global eradication. By the mid-
1970s, fewer than 50,000 cases 
were being reported annually in 
the United States, but a severe out-
break in Los Angeles in 1977 re-
minded authorities how tenuous 
the control of measles was. Com-
pulsory immunization of school-
children followed — the first in 
a series of steps that led to the 
interruption of the transmission 
of measles in the United States. 
The most effective of these steps 
was probably the introduction of 
a second dose of measles vaccine 
in 1989, again in response to a 
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large outbreak of disease. At a 
meeting in March 2000, leaders in 
the field concluded that “measles 
is no longer endemic in the U.S.”1
Six years later, an article in this 
issue of the Journal (pages 447–455) 
describes a 2005 measles outbreak 
in Indiana. Begun when a 17-year-
old girl who was incubating mea-
sles returned to Indiana from Ro-
mania, the outbreak ultimately 
involved at least 34 persons, 1 of 
whom had life-threatening illness. 
With U.S. vaccination coverage at 
record levels, how could one im-
ported case of measles lead to 
such an outbreak? This example 
illustrates the highly infectious 
nature of measles and the vulner-
ability of vaccinated communities 
in a world in which the virus con-
tinues to circulate.
Measles is an acute infectious 
disease that can affect persons of 
all ages but is most severe in young 
infants and adults. Person-to-per-
son transmission occurs through 
direct contact or droplet spread, 
and there is some evidence that 
severity is related to in-
fective dose, so that those 
who acquire the disease 
from close household 
contacts have the most 
severe disease.2 Infected 
persons can infect others 
during the prodromal 
period before the char-
acteristic rash appears, 
creating ample opportu-
nity for people who are 
incubating the disease to 
travel from a country 
where the virus is circu-
lating, such as Romania 
or India (the latter being 
the probable origin of an 
outbreak in Boston in 
the spring and early sum-
mer of 2006), and bring 
the virus with them.
In any population, there are 
persons who are immune to 
measles, thanks to natural in-
fection or immunization; per-
sons who are susceptible to the 
disease; and persons with incom-
plete immunity who may be sus-
ceptible to mild disease. In places 
where measles virus circulates 
freely, persons with immunity ap-
pear to have their immunity boost-
ed by intermittent exposure to the 
wild virus3; those who are suscep-
tible, meanwhile, will inevitably 
acquire the disease unless they are 
immunized. After the disease has 
swept through a community, very 
few persons will remain suscep-
tible. With time, however, new 
persons who are susceptible — 
who either have not been vacci-
nated or did not acquire protective 
immunity from the vaccine they 
did receive — will be introduced 
into the community. Their num-
bers will gradually increase until 
there are enough such persons 
to sustain an epidemic — hence 
the unstable measles epidemiol-
ogy found in partially vaccinated 
communities (see graph).
In countries such as the Unit-
ed States, where transmission of 
the wild virus has been interrupt-
ed, the rate of increase in the num-
ber of persons who are suscepti-
ble to the disease will depend on 
the success of the immunization 
program. For control to be sus-
tained, a two-dose vaccination 
strategy with very high coverage 
is needed.
At the time of the 2005 out-
break, the level of vaccination cov-
erage in Indiana was 98 percent 
for the second dose delivered to 
school-age children. In such a set-
ting, it can be expected that the 
number of vaccinated persons who 
do not acquire protective immu-
nity will be small, so the primary 
group of persons who are suscep-
tible to the disease will consist of 
those who are unvaccinated. An 
important subgroup will be chil-
dren who are too young to be vac-
cinated. These infants become 
susceptible when maternal im-
munity wears off, and they remain 
susceptible until they are immu-
nized.
There is evidence that mater-
nal immunity is declining in some 
countries because, without the 
boosting effect of circulating wild 
virus, mothers must rely on im-
munity from their own vaccina-
tions (which were usually deliv-
ered in the second year of life). 
As a result, infants become sus-
ceptible to measles earlier in the 
first year of life, thereby increas-
ing the number of susceptible per-
sons present in a community at 
any given time. The susceptibil-
ity of young infants is of partic-
ular concern, since they are more 
likely than older children to have 
severe disease if they become in-
fected.
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Fluctuation in the Number of Persons Susceptible to Measles 
in a Community Where Measles Virus Is Circulating.
In general, only a small fraction of the community will be suscep-
tible at the time of an outbreak. The horizontal double-pointed 
arrows represent periods between outbreaks of measles, which 
vary according to levels of vaccine coverage and other factors. The 
downward-pointing arrows represent outbreaks of measles.
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Furthermore, a generation of 
young adults with waning, vac-
cine-derived immunity may be-
come susceptible to some extent 
to wild measles infection, al-
though the role of such “second-
ary vaccine failures” in measles 
epidemiology is unclear. The lon-
ger a community goes without 
circulating measles virus, the more 
vigilant public health officials 
must be to maintain immunity 
levels in the community.
The Indiana outbreak was strik-
ing for a number of reasons. All 
but two of the cases occurred in 
unvaccinated hosts, indicating that 
it was the failure to vaccinate 
rather than vaccine failure that 
caused the problem. Five hundred 
people were reportedly present at 
the church gathering where the 
initial U.S. transmission occurred. 
Church officials estimated that 
10 percent of them were unvac-
cinated, but it is unclear how they 
knew this or how accurate their 
estimate was. It seems unlikely 
that the person with the index 
case of measles could have direct-
ly infected 32 percent of all sus-
ceptible persons at the meeting, 
and I would suggest that the 
number of unvaccinated persons 
there may have been higher. But 
even 10 percent is a high propor-
tion in a state with 98 percent 
coverage for the second dose of 
measles vaccine, despite the fluc-
tuations in coverage that may have 
occurred during the lifetimes of 
those who became infected, most 
of whom were younger than 20 
years old. 
Community-based data such as 
levels of vaccine coverage repre-
sent averages for a district, state, 
or country; although homogene-
ity may seem to be implied, it 
never exists. Moreover, objection 
to immunization tends to occur 
in clusters, sometimes affecting 
whole communities. Thus, even 
with excellent coverage, there re-
main subgroups in which condi-
tions suitable to an outbreak may 
persist. Large gatherings of these 
groups provide an ideal setting for 
transmission, and if a person who 
is incubating the disease attends 
such a gathering, an outbreak is 
inevitable.
Of the two vaccinated persons 
who acquired measles in Indiana, 
one was 34 years old and had been 
vaccinated only once in infancy. 
We cannot tell whether this case 
represents a primary vaccine fail-
ure (a failure of the vaccine to in-
duce immunity) or a secondary 
vaccine failure (the result of wan-
ing immunity). The severity of the 
case suggests the former, since 
secondary vaccine failures tend to 
produce mild disease.4 In addi-
tion, a 16-year-old student acquired 
measles despite having received 
two doses of measles vaccine dur-
ing early childhood.
In the United States, measles 
vaccine is delivered in combina-
tion with mumps and rubella 
vaccines. Although the two-dose 
strategy ensures that a high pro-
portion of vaccinees will be im-
mune to measles (seroconversion 
after two doses of vaccine is es-
timated to be 98 percent), the con-
version rate is lower for mumps 
(approximately 88 percent). Thus, 
the proportion of persons in a 
U.S. community who are suscep-
tible to mumps is greater than 
the proportion who are suscep-
tible to measles, and outbreaks, 
when they occur, will be larger. 
More than 50,000 cases of 
mumps have been identified in 
the United Kingdom during the 
past few years, and more than 
2500 cases have already been 
identified in a U.S. outbreak this 
year.5 About half the persons af-
fected in the U.S. outbreak had 
been vaccinated, and most were 
young adults. Although mumps is 
a less severe disease than measles, 
it does cause substantial illness, 
including parotitis, orchitis, and 
aseptic meningitis. These out-
breaks demonstrate the potential 
for rapid dissemination of respi-
ratory pathogens, facilitated by 
air travel and crowded conditions.
Despite the vision of the pub-
lic health officials of the 1960s, 
global eradication of measles re-
mains a long way off. In the mean-
time, countries must strive to im-
munize as high a proportion of 
children as possible, using a sec-
ond dose to minimize the risk of 
primary vaccine failure and im-
prove coverage. Better understand-
ing of the epidemiology of measles 
in vaccinated communities will 
permit the optimization of vac-
cination strategies. The importa-
tion of virus can be minimized by 
ensuring that travelers to and from 
regions where the viruses are en-
demic provide evidence of immu-
nization. Yet as long as measles 
continues to circulate in other 
parts of the world, cases will con-
tinue to be imported. And as long 
as some groups within a given 
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community respond to spurious 
claims about the risks of the vac-
cine by refusing to vaccinate their 
infants, further outbreaks will oc-
cur even in industrialized coun-
tries.
Dr. Mulholland is a professor in the Infec-
tious Disease Epidemiology Unit of the Lon-
don School of Hygiene and Tropical Medi-
cine, London.
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No Refuge for the Ailing
Ranjana Srivastava, F.R.A.C.P.
The still, oppressive heat of the afternoon seems to magnify 
the queue of waiting patients. A 
young woman separates herself 
from the crowd.
“Excuse me, Doctor, how long 
will you be?”
I answer with a f licker of an-
noyance, “I am not sure, but I will 
see you.”
An hour later, it is her turn. 
She looks far too well, I silently 
judge. The well worried. She 
springs from her seat at the sound 
of her name but moves away from 
me toward the stairs. There, she 
utters a rapid command in a for-
eign tongue before turning apol-
ogetically toward me. Before I can 
greet her, a scarf-clad head comes 
into view. It belongs to an elderly 
woman physically supported by 
aides on each side. The aides stop 
on the landing, then wordlessly 
and cautiously lift her up to carry 
her into the only chair in my of-
fice. Her features are wizened, 
her frame more shrunken than 
the six decades indicated on her 
chart would predict. Her eyes are 
dull, opaque, her face a repository 
of apprehension, anxiety, perhaps 
worse. She periodically glances at 
her daughter, but mostly she keeps 
her face averted as we settle into 
the consultation. The daughter 
speaks for her.
“I am sorry if I was rude, Doc-
tor. My mother has breast cancer, 
and she was waiting downstairs 
for a long time. We can’t afford to 
see anyone. We need your help.”
I am caught unaware.
This is a refugee clinic, run out 
of a makeshift health care facil-
ity as bare as any in the Third 
World. Volunteer physicians bring 
their own equipment and, often, 
spare drug samples. Limited num-
bers of doctors and meager do-
nations mean that we can barely 
treat hypertension, eczema, and 
headache; we are rarely able to 
provide refugees with anything 
remotely resembling the standard 
of care.
“We don’t do cancer,” I want 
to say, keen to end the conversa-
tion right there.
“Doctor, my mother has no 
one. We can’t pay the specialists. 
The emergency room bills us if it 
doesn’t turn us away. They said 
you would help.” Her tone com-
bines pleading with frustration 
and accusation. The mother winc-
es with pain. The daughter solici-
tously measures out some mor-
phine. As the patient swallows it 
with a wry face, the daughter 
murmurs, “This is the last mor-
phine. We have to wait now un-
til . . .”
“Until . . . ?”
“Until my husband’s disability 
pension arrives.”
She brusquely runs her hand 
across the involuntary tears that 
have started. Her mother’s hand 
surreptitiously reaches out to com-
fort her. In that moment, the enor-
mity and heartache of the situa-
tion descend on me, and Mrs. 
Habib becomes my patient.
Having lost all the male mem-
bers of her family through war, 
Mrs. Habib arrived from Afghan-
istan to live with her only daugh-
ter, an Australian resident. Here, 
her application for refugee status 
was denied on grounds of insuf-
ficient evidence, thus denying her 
access to any form of government 
support, including food, shelter, 
employment, and health care. 
While the decision is appealed on 
humanitarian grounds, a process 
that can take years, the restric-
tions continue. Reliance on the 
family’s small earnings worked 
until she developed cancer. A pub-
lic hospital provided her with a 
free mastectomy but no follow-up. 
Now she is riddled with painful 
bony metastases. I read letters 
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